TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AMGN

Amgen Inc

Healthcare · Drug Manufacturers - General

379.80$ +0.9% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Amgen Inc (AMGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.7% of the shares are freely tradable; institutional investors hold 85.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 85.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 541Mio.

Largest Shareholders

Institutions

Institutions AMGN
Name Stake (%) Shares Change (%) Date
BlackRock Inc 8.71 47,100,472 -0.6 03/31/2026
Vanguard Capital Management, LLC 6.48 35,014,232 +0.0 03/31/2026
State Street Corp 5.65 30,548,488 -0.1 03/31/2026
Capital World Investors 5.38 29,075,329 -0.7 06/30/2026
Amvescap Plc. 2.94 15,885,506 -5.9 03/31/2026
Morgan Stanley - Brokerage Accounts 2.93 15,836,058 +0.6 03/31/2026
Geode Capital Management, LLC 2.85 15,430,524 +7.9 03/31/2026
Vanguard Portfolio Management, LLC 2.70 14,621,148 +0.0 03/31/2026

Funds

Funds AMGN
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 3.18 17,186,059 +0.3 07/31/2026
Vanguard 500 Index Investor 2.62 14,169,752 +1.1 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings AMGN
Person Role Shares Value As of Type
Holley Charles M Director 12,990 4,933,774 $ Aug 7, 2026 direct
Miller Derek SVP, Human Resources 12,462 4,733,068 $ Aug 6, 2026 direct
Ishrak Omar Director 7,486 2,843,147 $ Aug 7, 2026 direct
Grygiel Nancy A. SVP & CCO 7,340 2,787,732 $ Aug 6, 2026 direct
Khosla Rachna SVP, Business Development 6,404 2,432,239 $ Aug 13, 2026 direct
Drake Michael V Director 5,876 2,231,767 $ Aug 7, 2026 direct
Busch Matthew C. VP, Finance & CAO 5,080 1,929,384 $ Aug 7, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Aug 13, 2026 Khosla Rachna SVP, Business Development Sell 1,252 416.43 521,365
Aug 13, 2026 Khosla Rachna SVP, Business Development Other 1,252 162.60 203,575
Aug 11, 2026 Khosla Rachna SVP, Business Development Sell 2,000 412.57 825,134
Aug 7, 2026 Busch Matthew C. VP, Finance & CAO Other 730 0.00
Aug 7, 2026 Ishrak Omar Director Other 85 0.00
Aug 7, 2026 Holley Charles M Director Other 103 0.00
Aug 7, 2026 Drake Michael V Director Other 64 0.00
Aug 6, 2026 Miller Derek SVP, Human Resources Sell 1,821 402.54 733,033
Aug 6, 2026 Miller Derek SVP, Human Resources Other 1,821 177.46 323,155
Aug 6, 2026 Miller Derek SVP, Human Resources Sell 2,069 402.54 832,864
Aug 6, 2026 Miller Derek SVP, Human Resources Other 2,069 162.60 336,419
Aug 6, 2026 Grygiel Nancy A. SVP & CCO Sell 1,000 402.16 402,160
Aug 6, 2026 Grygiel Nancy A. SVP & CCO Other 1,000 177.31 177,310
Aug 6, 2026 Grygiel Nancy A. SVP & CCO Sell 1,970 402.16 792,255
Aug 6, 2026 Grygiel Nancy A. SVP & CCO Other 1,970 177.46 349,596

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?